Biotechnology
Medical
Pharmaceutical

Rigel Pharmaceuticals

$2.13
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.12 (5.94%) Today
-$0.01 (-0.47%) After Hours

Why Robinhood?

You can buy or sell RIGL and other stocks, options, ETFs, and crypto commission-free!

About

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. Read More The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Employees
158
Headquarters
South San Francisco, California
Founded
1996
Market Cap
357.76M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
2.24M
High Today
$2.26
Low Today
$2.07
Open Price
$2.11
Volume
720.33K
52 Week High
$3.94
52 Week Low
$1.96

Collections

Biotechnology
Medical
Pharmaceutical
Therapy
Health
Technology

News

Seeking AlphaMay 16

Rigel begins patient enrollment in late-stage AHIA study

Rigel Pharmaceuticals (NASDAQ:RIGL) has enrolled first patient in a Phase 3 trial of fostamatinib disodium hexahydrate in warm antibody autoimmune hemolytic anemia (AIHA). The trial protocol calls for ~80 patients in a 24-week study with topline results projected for early 2021. The primary endpoint will be a durable hemoglobin response by week 24, defined as Hgb > 10 g/dL and > 2 g/dL greater than baseline. Currently, fostamatinib is commercially available in U.S. under the brand name TAVALISSE. Rigel ...

566
Seeking AlphaMay 10

Rigel Reports An Earnings Beat, But The Market Shrugs It Off

Despite the positive updates, the share price remains in the lower $2.00 range. However, the charts show a systematic chart movement that is leading to a potential breakout. TAVALISSE appears to be gaining traction in the ITP market as physicians begin to move it up into earlier lines of therapy and above the competition. Rigel recently reported their Q1 earnings with a beat on EPS and revenue. Despite the good news, the market was unconcerned as the overall market is focused on trade talks. Rigel Pharma...

458
The Motley FoolMay 8

Rigel Pharmaceuticals Inc (RIGL) Q1 2019 Earnings Call Transcript

269

Earnings

-$0.18
-$0.11
-$0.04
$0.03
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.